Otsuka Pharmaceutical Co., Ltd. today announces that its U.S.-based indirect subsidiary Avanir Pharmaceuticals, Inc. has agreed with Optinose, Inc. to return to Optinose the rights in North America to ONZETRA^®Xsail^® for the acute treatment of migraines in adults.

Avanir comprehensively reevaluated the U.S. migraine medication market. As a result, the decision was made to terminate the licensing agreement.